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Morroniside is one of the most important iridoid glycosides in the herbal drug Cornus ofﬁcinalis Sieb. et
Zucc. The current study was designed to investigate the ex vivo and in vivo effects of morroniside on
CYP3A activity in rats after treatment with morroniside for 7 days (at 10, 30, 90 mg/kg, i.g.). Morroniside
was found to induce CYP3A. According to the ex vivo experiment, the activity of CYP3A was measured by
the quantiﬁcation of 1-hydroxymidazolam, which was the metabolite from CYP3A probe substrate,
midazolam. The concentration of 1-hydroxymidazolam was determined by using a validated liquid
chromatography coupled with tandem mass spectrometry detection (LC-MS/MS) method. The levels of
messenger RNA (mRNA) and protein of CYP3A were determined by reverse transcriptase-polymerase
chain reaction (RT-PCR) and western blotting analysis, respectively. The pharmacokinetics of mid-
azolam in rats after treatment with morroniside for 7 days (at 10, 30, 90 mg/kg, i.g.) were investigated
in vivo. After treatment with morroniside, the activity, mRNA and protein expression of CYP3A were
signiﬁcantly induced and the absorbance and bioavailability of midazolam in rats were reduced. The
results indicated that morroniside could induce the activity of CYP3A.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Fructus Corni, named Shan-Zhu-Yu in Chinese, is the dried sar-
cocarp of Cornus ofﬁcinalis Sieb. et Zucc. It has been used for
thousands of years as an important traditional Chinese medicine in
China, which exhibits a number of biological activities, including
immunological regulation, antishock, antiarrhythmia, antibiosis,
hypoglycemic, etc (1, 2).
Morroniside is one of the most important iridoid glycosides,
which are extracted from sarcocarp of C. ofﬁcinalis. Its chemical
structure is shown in Fig. 1 (3). Morroniside has been proved to be
effective in invigorating stomach (4), preventing diabetic angio-
pathies (5) and renal damage (6), inhibiting lipid metabolism and
inﬂammation (7) and reducing bone resorption (8). In recent
studies, it was also reported that morroniside had signiﬁcant
neuroprotective effect (9e11). Extensive studies have been carried
out to investigate the pharmacokinetics of morroniside (3, 12, 13),
but the direct relationship between morroniside and cytochrome. Zhang).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).P450 is unclear. The interaction between morroniside and cyto-
chrome P450may cause herb-drug interaction, andmay potentially
explain the use of herb-drug combination.
Using a probe substrate to determine the metabolic activities of
cytochrome P450 is used widely in present drugedrug interaction
studies. In this study, the effects of morroniside on the activity,
mRNA and protein expression of CYP3A were investigated ex vivo
by using rat liver microsomes. The effects of morroniside on the
metabolism of midazolam, the probe substrate of CYP3A, were
investigated in vivo. Combined ex and in vivo parameters might
better reveal the potential of direct induced effects of morroniside
on CYP3A in rats.2. Materials and methods
2.1. Experimental animals
Male SpragueeDawley rats (200e240 g) were provided by
Beijing Institute of Pharmacology and Toxicology (Certiﬁcate no.
SCXK 2012e0004). Rats were housed in cages with 12 h day light/
12 h night cycle at ambient temperature (about 23e25 C). Animals
had free access to tap water and commercially available standardnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Chemical structure of morroniside.
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Center for Drug Safety Evaluation followed the protocol of the
Institutional Animal Care and Use Committee of the Centre, which
was in compliance with the guidelines of the Association for
Assessment and Accreditation of Laboratory Animal Care
International.
2.2. Chemicals and reagents
Morroniside was extracted and puriﬁed from sarcocarp of C.
ofﬁcinalis by the department of pharmacology, Xuanwu Hospital of
Capital Medical University and its purity was over 98.5% by HPLC
analysis. Midazolam and dexamethasone were purchased from the
National Institute for the Control of Pharmaceutical and Biological
Products. NADPHwas obtained fromRoche Diagnostics Ltd (Beijing,
China). 1-Hydroxymidazolamwas purchased from Sigma Chemical
Company (St Louis MO, USA). Anti-CYP450 3A antibody was pur-
chased from Abcam Ltd (Cambridge, UK). Mouse monoclonal
antibody reactive against rat b-actin was from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Acetonitrile, formic acid
and ammonium formate were purchased from Fisher Scientiﬁc
(Fair Lawn, NJ, USA). All other chemicals were of analytic grade or
better.
2.3. LC-MS/MS method
CYP3A activity was quantiﬁed by measuring the extent of 1-
hydroxymidazolam formation from midazolam. It was quantita-
tively analysed by a Finnigan TSQ Quantum LC-MS/MS system
(Thermo, USA). The separation of midazolam,1-hydroxymidazolam
and L-phencynonate (internal standard) was achieved by using a
BioBasic-18 column (2.1  50 mm, 5 mm, Thermo) and a mobile
phase gradient (A: water with 0.1% formic acid; B: acetonitrile with
0.1% formic acid). An elution lasting 4.5 min was carried out. The
test was accomplished by a mass spectrometer using selected re-
action monitoring (SRM) in positive mode.
2.4. Preparation of rat hepatic microsomes
Rats were randomized into 5 groups (n ¼ 3 per group) receiving
control vehicle, dexamethasone at 100 mg/kg/day, for 4 consecu-
tive days, intraperitoneally and morroniside at 10, 30 or 90 mg/kg/
day by gavage for 7 consecutive days. On day 8, rats were fasted
overnight with free access to water for at least 12 h. Before ho-
mogenized, the livers were perfused by ice phosphate buffer
(0.1 mM, pH 7.4) through portal vein. The livers were collected and
transferred to ice immediately after the surgical excision, cut into
pieces, and stored at 80 C until the microsomes were prepared.After liver samples were thawed and weighed, 3vols of ice-cold
homogenization medium (50 mM TriseHCl buffer at pH 7.4 con-
taining 0.25M sucrose) were added. The tissue was chopped using
scissors and homogenized with an automatic homogenizer at
500 rpm (IKA Labortechnik, Staufen, Germany). The homogenate
was centrifuged at 10 000 r/min for 20 min at 4 C using a Beckman
centrifuge (Beckman Coulter, Inc., Fullerton, CA, USA). Then the
supernatant was centrifuged at 105 000 r/min for 60 min at 4 C
using an L8-70 Beckman ultracentrifuge. The resulting microsomal
pellet was resuspended with the above homogenizing buffer. And
the microsomal suspensions were stored at 80 C (14). Protein
concentrations of microsomes were determined by using the Lowry
method (15).
2.5. Measurements of CYP3A activity
The activity of CYP3Awas characterized by themetabolism of the
probe substrate, midazolam. The 250 mL reaction mixture contained
potassium phosphate buffer (pH 7.4, ﬁnal concentration z 0.1 M),
microsomal protein (ﬁnal concentration z 0.5 mg/mL), NADPH
(ﬁnal concentration z 10 mM) and midazolam (ﬁnal
concentration z 5 mM). The mixture was pre-incubated in a 37 C
water bath with gentle shaking for 5 min before addition of NADPH.
Then the reaction was initiated by addition of 10 mM NADPH and
terminatedwith addition of 750 mL ice-chilled acetonitrile containing
80ng/mL L-phencynonate after 60min incubation. Themetabolites of
the CYP3A probe substrate from all incubation were determined by
previously well-validated sensitive LC-MS/MS method. The tubes
were vortex-mixed for 1 min and centrifuged at 14 000 r/min for
10 min, and 15 mL of the supernatant was analysed.
2.6. Determination of mRNA levels by RT-PCR
Approximately 100e200 mg of liver tissue was homogenized
and total RNA was isolated with the Trisol reagent (Invitrogen,
Carlsbad, CA, USA). The RNA concentrationwas determined and the
quality of RNA solutions was assessed by an ultraviolet light spec-
trophotometer. For reverse transcription, 1 mL of RNA was used in a
20 mL reaction mixture utilizing RevertAid™ M-MuLV RT (Fer-
mentas, Hanover, MD, USA) according to the supplier's instructions.
The typical reaction mix (ﬁnal volume ¼ 20 mL) contained 10 mL of
Platinum SYBR Green qPCR SuperMix-UDG, 2 mL each of the for-
ward and reverse primers and DEPC-treated water. The reverse
transcription reaction was performed for 5 min at 25 C, 30 min at
42 C and 5 min at 85 C (16).
2.7. Western blotting analysis
Liver microsomes were prepared from rats in all groups. The
proteins were subjected by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Sodiumdodecyl
sulphate (SDS)-PAGE was performed as described (17). Membrane
was incubated overnight at 4 C with mouse monoclonal antibody
against rat CYP3A at 1:1000 dilution in TBS containing 5% milk. At
the end of the incubation, the membrane was rinsed with TBS and
incubated for 90min at room temperature with the secondary anti-
rabbit antibody conjugated with horseradish peroxidase. Gel image
was visualized using Chem-Doc (Bid-Rad) and signal intensity of
immunoreactive bands was analyzed by Quantity One software
(Bid-Rad) (18e20).
2.8. Effect on the pharmacokinetics of midazolam
The pretreatment was the same as above. Midazolam was dis-
solved to 5 mg/mL in ethanol and then slowly diluted to 0.25 mg/
S. Xiong et al. / Journal of Pharmacological Sciences 127 (2015) 414e418416mL with 0.9% Sodium chloride injection. After the 7 day treatment,
a single midazolam (2.5 mg/kg, intragastric administration) was
given. Blood samples (0.3 mL) were collected via the jugular vein
before and at 2, 5, 15, 30, 60, 120, 240 and 360 min after midazolam
administration and the heparin was used as an anticoagulant. The
same volume of saline was added each time after a blood sample
was collected. Plasma was obtained from the samples by centrifu-
gation at 3000 r/min for 15 min at 4 C. Samples were prepared
using the standard protein precipitation method consisted of
adding 100 mL of plasma to a centrifuge vial, followed by 300 mL of
acetonitrile containing 80 ng/mL L-phencynonate. The tubes were
vortex-mixed for 1 min and centrifuged at 14 000 r/min for 10 min
and 15 mL of the supernatant was analysed. All the data were pro-
cessed by non-compartmental analysis using the DAS 2.0 package
(Mathematical Pharmacology Professional Committee of China,
Shanghai, China).Fig. 3. Relative mRNA expression of CYP3A. Rats were pretreated with morroniside
(10, 30 and 90 mg/kg/d, i.g., 7d) or dexamethasone (100 mg/kg/d, i.p., 4d) and the
control group. Dexamethasone group was used as the positive group. Data are
mean ± SD. n ¼ 3. *p < 0.05, **p < 0.01, compared with control (saline treatment).2.9. Statistics
Experimental data were expressed as mean ± standard devia-
tion (SD) of three replicates. Statistical analyses were performed
with Microsoft Ofﬁce Excel 2003. The significance of the difference
between groups for continuous variables was evaluated with
analysis of variance (ANOVA). Differences between two groups
were analysed using the t-test. A value of p < 0.05 was considered
as statistically signiﬁcant.3. Results
3.1. Effect of morroniside treatment on rat CYP3A activity
CYP3A activity was evaluated by comparing the amount of 1’-
hydroxymidazolam in control group, morroniside treatment
groups and dexamethasone treatment group. Rat CYP3A activity
was increased 2.57-fold by dexamethasone treatment. Compared
with the control, CYP3A activity was increased 1.51-,1.89- and 2.31-
fold by morroniside treatment at 10, 30 and 90 mg/kg/day,
respectively (Fig. 2).Fig. 2. Relative activity of CYP3A after morroniside treatment in rats. Rats were pre-
treated with morroniside (10, 30 and 90 mg/kg/d, i.g., 7d) or dexamethasone (100 mg/
kg/d, i.p., 4d) and the control group. Dexamethasone group was used as the positive
group. The activity of CYP3A was evaluated by the formation rate of 1-
hydroxymidazolam. Data are mean ± SD. n ¼ 3. *p < 0.05, **p < 0.01, compared
with control (saline treatment).3.2. Effect of morroniside treatment on rat CYP3A mRNA expression
The effects of morroniside treatment on the expression of
CYP3Awere examined. Total RNAwas extracted from liver samples
in all groups. cDNAswere prepared by reverse transcription and the
levels of CYP3A mRNA were determined by RT-PCR. The mRNA
levels of CYP3A signiﬁcantly increased in morroniside treatment
group compared with the control group (Fig. 3). Morroniside
treatment at 10, 30 and 90 mg/kg/day increased the mRNA
expression of CYP3A 1.13-, 1.43- and 1.79-fold, respectively,
whereas dexamethasone treatment increased the mRNA expres-
sion 2.35-fold.
3.3. Effect of morroniside treatment on rat CYP3A protein
expression
Consistently, western blotting analysis showed that protein
levels of CYP3A were signiﬁcantly increased in rats treated with
morroniside (Fig. 4). The CYP3A content in hepatic microsomes of
rats treated with morroniside at 10, 30 and 90 mg/kg/day increased
1.23-, 1.41- and 1.44-fold, respectively, whereas dexamethasone
treatment increased the protein expression 1.66-fold.
3.4. Effect of morroniside treatment on the pharmacokinetics of
midazolam
To obtain further information of the effect of morroniside on the
activity of CYP3A, an in vivo study was also carried out. CYP3AFig. 4. Protein expression of CYP3A. Rats were pretreated with morroniside (10, 30 and
90 mg/kg/d, i.g., 7d) or dexamethasone (100 mg/kg/d, i.p., 4d) and the control group.
Dexamethasone group was used as the positive group. GAPDH was used as control for
the normalization of CYP3A density.
Fig. 5. Plasma concentrationetime proﬁles of midazolam. Rats were pretreated with
morroniside (10, 30 and 90 mg/kg/d, i.g., 7d) or dexamethasone (100 mg/kg/d, i.p., 4d)
and the control group. Dexamethasone group was used as the positive group. On the
eighth day, rats were given a single midazolam (2.5 mg/kg, i.g.). The concentration of
midazolam in every group was compared with the control group (saline treatment).
Values are expressed as mean ± SD. for each data point (n ¼ 3).
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of midazolam in all groups after treatment with morroniside. Fig. 5
showed the plasma concentrationetime proﬁles of midazolam. 7-
day treatment of morroniside also decreased the AUC(0e6h) of
midazolam. The AUC(0e6h) of midazolam with no morroniside
treatment was 5283.76 ± 1514.82 min  ng/mL, compared with
4122.56 ± 126.29 min  ng/mL after 10 mg/kg morroniside treat-
ment (a decrease of 21.98%), 2565.69 ± 30.93 min  ng/mL after
30 mg/kg morroniside treatment (a decrease of 51.44%),
2065.34 ± 430.46 min  ng/mL after 90 mg/kg morroniside treat-
ment (a decrease of 60.91%) and 1980.74 ± 244.00 min  ng/mL
after 100 mg/kg dexamethasone treatment (a decrease of 62.51%).
Treatment with morroniside at different doses increased the
clearance (CL) of midazolam. The MRT decreased by 33.39% and
25.06% after treatment with 30 mg/kg and 90 mg/kg morroniside,
respectively. Listed in Table 1 and Fig. 5.4. Discussion
Many researches had shown that cytochrome P450 enzymes
could be induced or inhibited by some drugs. The changes of
cytochrome P450 levels or activities could affect the drug con-
centration of blood, the pharmacokinetic process and biological
medicinal properties (21). Europe and the United States require
that drug screens and metabolic researches based on the
cytochrome P450 system should contain new drugs evaluations
(22). This methodology for pharmacokinetic research in newTable 1
Pharmacokinetics of midazolam after a 7 day treatment with morroniside in rats (mean
Parameter Unit Control Low (10 mg/kg)
Cmax mg/L 51.58± 24.19 33.78± 7.02
Tmax min 16.67± 5.77 26.67± 5.77
MRT(0-6h) min 113.68± 10.88 106.97± 24.49
T1/2 min 115.41± 69.09 114.16± 30.91
Cl/F L/min/kg 0.51± 0.17 0.61± 0.02
AUC(0-6h) min  mg/L 5283.76± 1514.82 4122.56 ± 126.29
*p< 0.05, **p< 0.01, compared with control (saline treatment).chemical drugs development was also required by the Chinese
CFDA.
The concomitant treatment of herbal supplements and syn-
thetic drugs had become popular. Chinese herbal medicines con-
tained various biologically active ingredients. As a result, the herb-
drug interactions had become a common clinical problem. Some
studies reported that the mechanisms underlying the interaction
between herbal medicines and conventional drugs mainly involved
induction or inhibition of the activities of metabolic enzymes and
drug efﬂux proteins. Therefore, potential herb-drug interactions
involving Chinese herbal medicines were worthy to study the cy-
tochrome P450 system (23).
For the ﬁrst time, we systematically investigated the effects of
morroniside on the activity of CYP1A2, CYP2B6 and CYP3A in rats.
The results of the study revealed the morroniside caused a dose-
dependent induction of CYP3A activity, but it had no effect on
CYP1A2 and CYP2B6 (data not published). Furthermore, we had
shown that the morroniside treatment increased CYP3A protein
andmRNA expression in rats. In this research, the antibodywe used
was not speciﬁc enough to distinguish CYP3A1 and CYP3A2, which
were two main CYP3A isoforms and shared an 89% sequence sim-
ilarity (24).
In vivo study showed that the CYP3A activity was increased,
when morroniside (10, 30 and 90 mg/kg, i.g.) was daily for seven
consecutive days. Further, RT-PCR analysis showed that the in-
duction of mRNA expression by morroniside (10, 30 and 90 mg/kg,
i.g.) was 1.13-, 1.43- and 1.79-fold higher, respectively, relative to
the control. And the western blot analysis showed that the induc-
tion of protein expression by morroniside was 1.23-, 1.41- and 1.44-
fold higher, respectively. The results were well correlated with the
observed CYP3A activity increase. The observed AUC0e6h of mid-
azolam in morroniside treated rats also indicated that morroniside
indeed enhanced the CYP3A activity. The dexamethasone treated
rat model was widely used for induction of CYP3A activity (25). In
this model, as plasma concentration of midazolam depended upon
CYP3A activity, the observed effects of dexamethasone on the AUC
of midazolam were well in accordance with the earlier report (26).
The above ﬁndings showed that morroniside treatment could
induce the CYP3A activity. So, it needed to pay attention to the
drugedrug interactions.5. Conclusions
CYP3A was an important member of the cytochrome P450 su-
perfamily. In this study, we investigated the potential inﬂuence of
morroniside on CYP3A in rats after multiple doses of morroniside
(at 10, 30, 90 mg/kg, i.g., 7d), based on the CYP3A activity, mRNA,
protein expression and pharmacokinetic behaviours of midazolam
in rats. The morroniside treatment was shown to induce CYP3A
activity. The results might provide a scientiﬁc explanation for
traditional Chinese medicine compatibility.± SD, n ¼ 3).
Medium (30 mg/kg) High (90 mg/kg) Positive control
25.93± 8.94 14.28± 4.70* 12.19± 3.17*
23.33± 5.77 20.00± 0.00 23.33± 5.77
75.72± 16.23* 85.19± 7.19** 132.39± 5.94*
71.43± 18.01 99.66± 83.09 138.71± 40.81
1.13± 0.26* 1.16± 0.22** 2.05± 0.83*
2565.69± 473.33* 2329.91± 236.61* 1980.74± 244.00*
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